GlobeNewswire

Hemp Hop’s First 420 Deals in Houston, TX - Buy 3 Get 1 Free 2026
16/04/2026
HOUSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Hemp Hop, Houston's newest cannabis dispensary , is proud to launch its first ever 420 deals in Houston , TX . At a time when the Texas hemp community has faced significant [...]
EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026
16/04/2026
, April 16, 2026 (GLOBE NEWSWIRE) -- EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026 Company to host conference call and webcast on Thursday, May 7 at 8:30 a.m. EDT AUSTIN, Texas, April 16, 2026 -- [...]
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
16/04/2026
MELBOURNE, Australia and SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]
Kane Biotech Presents revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Spring Conference
16/04/2026
>20 year‑old venous leg ulcers show dramatic healing and pain elimination with revyve Thermoreversible revyve transforms deep tunneling wound care, delivering 90% wound volume reduction revyve rapidly normalizes [...]
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
16/04/2026
EMERYVILLE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative [...]
Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
16/04/2026
SINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative [...]
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
16/04/2026
Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company’s lead candidate, intranasal foralumab, for Long COVID associated “brain fog”. BOSTON, April 16, 2026 ( [...]
ATUM Welcomes Gavin Barnard, Ph.D., as Chief Scientific Officer
16/04/2026
Newark, CALIFORNIA, April 16, 2026 (GLOBE NEWSWIRE) -- ATUM announced today the appointment of Gavin Barnard, Ph.D., as Chief Scientific Officer (CSO). In this role, Dr. Barnard will lead ATUM’s scientific strategy and [...]
Harrow Announces the Issuance of J-Code for IOPIDINE® 1%
16/04/2026
Reimbursement for Office-Based Utilization to Begin in July 2026 NASHVILLE, Tenn., April 16, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America [...]
Soleo Health Appoints Joy Rowan as New Senior Vice President of Sales to Drive Strategic Growth Initiatives
16/04/2026
FRISCO, Texas, April 16, 2026 (GLOBE NEWSWIRE) -- Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, today announced the appointment of Joy Rowan, MS, MBA to the role of [...]
Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders
16/04/2026
CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF ), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company” ), a [...]
Remedy Plan Therapeutics Announces Multiple Presentations at the AACR Annual Meeting 2026
16/04/2026
GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Remedy Plan Therapeutics, a clinical-stage biotechnology company developing novel therapies that target fundamental metabolic vulnerabilities in disease, today [...]
Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases
16/04/2026
Interim data to date showed 90% concordance with MRI (the primary endpoint) Clinical trial readout (Primary endpoint) expected in June 2026 Plans to advance RAD 101 into U.S. Phase 3 pivotal trial SYDNEY, April 16, 2026 [...]
Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England Journal of Medicine
16/04/2026
This press release is not intended for US or UK media. Ingelheim, Germany and Ridgefield, Conn. Boehringer Ingelheim today announced that The New England Journal of Medicine (NEJM) published results from the Phase 1b [...]
Eton Pharmaceuticals Announces CFO Succession Plan
16/04/2026
Experienced pharmaceutical executive Judith M. Matthews to assume CFO role on June 1st DEER PARK, Ill., April 16, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an [...]
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
16/04/2026
Patent covers use of AI in workflows of future products to accelerate company’s ability to scale and enhance already strong gross margins Expands intellectual property portfolio to 64 issued and pending patents [...]
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
16/04/2026
Aligos to receive an upfront payment of $25M USD Up to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit royalties Amoytop to fund its development program in Greater China [...]
Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026
16/04/2026
The U.S. Food and Drug Administration has granted Priority Review for Aicuris’ New Drug Application for pritelivir, a novel helicase primase inhibitor developed to treat refractory herpes simplex virus infections, with [...]
Alethio Therapeutics Unveils ATX‑011, a Breakthrough, Mutation‑Agnostic Antibody for Treating Essential Thrombocythemia – a c.$2B Market, and Strengthens Leadership to Accelerate Path to IND
16/04/2026
Oxford, UK – 16th April 2026 - Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX‑011, a first‑in‑class, mutation‑ [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum